FROM EVIDENCE-BASED DATA TO CLINICAL PRACTICE: SAFETY AND EFFICACY OF SUPRACILIARY MIGS

Presenting Author: Michel Vanbrabant
Country: Belgium
mailto:ornella.bua@istar-medical.com

iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject®, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness – and we are aiming to seek market approval in the US. We believe MINIject®’s distinctive tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of potentially leading products such as MINIject® to establish new treatment paradigms in eye care conditions with the highest patient needs.

About MINIject®

MINIject® is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject® combines the distinctive porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.

About Glaucoma

Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.2,3 IOP reduction, through medication or surgery, helps delay disease progression.4 Medication is generally the first line treatment, but the progressive addition of multiple drops can burden patients with side effects, compliance challenges and costs.3,4 Invasive surgery can present risks with irreversible complications and often requires long-term patient management.3,4 MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.3 MINIject is potentially best-in-class for its promising long-term efficacy and safety.

2 Jonas JB, Aung T, Bourne RR et al. “Glaucoma”. Lancet 2017; 390: 2083–93

3 Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021.  https://www.market-scope.com/pages/reports/267/2021-glaucoma-surgical-device-market-report

4 “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73